Cosmetic giants including L'Oreal, Galderma, and Natura are adjusting product strategies to capture demand from users experiencing skin sagging after taking GLP-1 weight-loss drugs. With the aesthetic treatment market for weight-loss patients projected to hit $2 billion in five years, companies are investing in new research. However, medical experts remain cautious about whether current topical beauty products can effectively address the deep structural skin changes caused by rapid weight reduction.
Major cosmetic companies are moving to address a specific aesthetic concern colloquially known as 'Ozempic face,' where patients report skin sagging and loss of facial volume after taking GLP-1 weight-loss medications. While the term describes a physical effect of rapid weight loss rather than a direct chemical impact of the drugs, the commercial potential is attracting significant corporate attention. Analysts project that the market for aesthetic treatments linked to this specific weight-loss demographic could grow from $700 million to $2 billion over the next five years.
Galderma, which is 20% owned by L'Oreal, is currently evaluating how its existing injectable products, such as Sculptra and Restylane, perform on patients who have undergone significant weight changes. The company is coordinating with thousands of medical practitioners to better understand how to address skin dullness and loss of firmness in this patient group. Similarly, L'Oreal has launched dedicated studies to observe skin effects on GLP-1 users to help refine its product development. Brazilian beauty firm Natura is also entering this space, testing its current product lines while exploring new formats, including potential ingestibles to supplement topical skincare.
Despite the corporate enthusiasm, medical experts are urging caution regarding the limitations of current beauty solutions. Dermatologists emphasize that while surface-level creams and serums may improve skin appearance, they cannot fix deep structural issues or replace the fat pads lost during rapid thinning. Because many users of these medications also fall into age brackets where collagen and estrogen levels naturally decline, isolating the specific impact of weight loss from standard aging processes is complex. This creates a challenge for companies aiming to design products that specifically target these weight-loss side effects.
For investors, the key to tracking this trend will be the actual clinical performance of these products and consumer adoption rates. Success will depend on whether companies can provide data to prove their offerings provide real benefits for this specific group or if the results are limited to general skin improvements. Regulatory scrutiny regarding marketing claims for anti-aging and skin-firming products will also be a critical factor to monitor, as health authorities often keep a close watch on product efficacy in the aesthetics sector.